{"filings":[{"id":778998,"accession_number":"0000105770-26-000080","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-06-01T20:32:30+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michel Lagarde appointed President & CEO of West Pharmaceutical, effective Aug 31, 2026.","Eric Green retires as President, CEO and Board Chair; Robert F. Friel becomes Board Chair.","Employment agreement: $1,175,000 base salary; target annual incentive 125% of base; 2026 LTI grant valued at $8,611,111.","Lagarde receives inducement equity awards up to $10M, including sign-on grant of $6,875,000 and matching RSUs/options.","Lagarde previously served as EVP & COO at Thermo Fisher Scientific; holds BBA from European University Antwerp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554236,"accession_number":"0000105770-26-000077","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K/A","filed_at":"2026-05-20T20:04:33+00:00","items":["1.05","9.01"],"status":"ready","headline":"West Pharmaceutical provides update on May 4 cyberattack; fully operational, no material financial impact","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Cybersecurity incident detected on May 4, 2026 involved data exfiltration and system encryption.","Company activated response, took systems offline globally; core enterprise and manufacturing systems restored.","All manufacturing, supply chain, and commercial sites globally are now fully operational.","No unauthorized access observed since May 5; investigation continues but incident not expected to materially affect Q2 or FY 2026 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15161,"accession_number":"0000105770-26-000068","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-05-11T21:06:38+00:00","items":["1.05","7.01","99.1","9.01"],"status":"ready","headline":"West Pharmaceuticals discloses material cyberattack; data exfiltrated, systems encrypted on May 4 2026","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Incident detected May 4, 2026; determined material on May 7, 2026.","Unauthorized party exfiltrated data and encrypted systems; company took systems offline globally for containment.","Engaged Palo Alto Networks' Unit 42 for investigation, containment, and recovery; law enforcement notified.","Business operations temporarily disrupted globally; core systems restored, but shipping/receiving/manufacturing restarted at some sites only.","Financial and operational impact not yet determined; investigation ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90977,"accession_number":"0000105770-26-000056","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"West Pharmaceutical holds 2026 annual meeting; all proposals pass except shareholder chair proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eleven directors elected to one-year terms; all received majority support with >57M votes each.","Non-binding say-on-pay approved with 60.1M for, 3.8M against, 80K abstain.","Ratification of PwC as auditor for FY2026 passed with 58.5M for, 7.6M against.","Shareholder proposal for independent board chair policy not approved: 29.6M for, 34.2M against.","Total shares represented: 66.2M (91.83% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90976,"accession_number":"0000105770-26-000047","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)","High-Value Components revenue $409.3M (+29.6%); HVP Delivery Devices $123.6M (+29.0%); West Vantage $150.6M (+11.6%)","Raised FY26 net sales guidance to $3.295-3.350B (prev $3.215-3.275B) and adj. EPS to $8.40-8.75 (prev $7.85-8.20)","Repurchased 1.2M shares for $297.6M at avg $243.57/share under February 2026 buyback program","Q2 2026 guidance introduced: net sales $830-850M, adj. EPS $2.05-2.12; SmartDose sale to AbbVie expected mid-year"],"consensus_eps_estimate":1.6935,"consensus_eps_actual":1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":844900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100845,"accession_number":"0000105770-26-000041","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","7.01","99.1","9.01"],"status":"ready","headline":"CEO Eric M. Green to retire; West reaffirms 2026 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric M. Green informed Board on March 6, 2026 of plan to retire as President, CEO and Chair after successor is hired, expected H2 2026.","Board is engaging a leading executive recruiting firm to find successor; transition aimed at smooth handoff.","Company reaffirms 2026 financial guidance issued on February 12, 2026; no change to outlook.","Green served as CEO since April 2015, Chair since May 2022; TSR ~350% during his 11-year tenure and sales more than doubled.","Lead Independent Director Robert F. Friel thanked Green for his service and highlighted company's innovation and pandemic response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100844,"accession_number":"0000105770-26-000005","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).","Full-year 2025: net sales $3.074B (+6.3%); diluted EPS $6.79 (+1.5%), adj-diluted EPS $7.29 (+8.0%).","FY2026 guidance: net sales $3.215B-$3.275B (4.6%-6.5% growth); adj-diluted EPS $7.85-$8.20 (+7.7%-12.5%).","Operating cash flow $754.8M (+15.5%); free cash flow $468.9M (+69.6%); repurchased 552,593 shares for $134M.","Expects mid-2026 close of SmartDose 3.5mL sale to AbbVie; device generated $55M in H2 2025."],"consensus_eps_estimate":1.8506,"consensus_eps_actual":6.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":3074100000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117141,"accession_number":"0000105770-25-000090","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q3 net sales $804.6M (+7.7%), adjusted EPS $1.96; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Proprietary Products HVP Components net sales $390M, +16.3% YoY, driven by GLP-1 products and HVP conversion.","Full-year 2025 net sales guidance raised to $3.060-3.070B; adjusted EPS guidance raised to $7.06-7.11.","Q4 2025 guidance: net sales $790-800M, adjusted diluted EPS $1.81-1.86.","Free cash flow nine months $293.9M, +53.7% YoY; repurchased 552,593 shares for $134.0M."],"consensus_eps_estimate":1.6984,"consensus_eps_actual":4.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":2269100000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133594,"accession_number":"0000105770-25-000083","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"General Counsel Kimberly Banks MacKay departing; transition through Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberly Banks MacKay, SVP, General Counsel & Corporate Secretary, is leaving West Pharmaceutical.","Transition period agreed, ending no later than December 31, 2025.","MacKay will continue her current duties until departure.","Company expressed gratitude for her service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133593,"accession_number":"0000105770-25-000062","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma beats Q2, raises FY 2025 guidance; declares Q4 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $766.5M (+9.2% YoY); diluted EPS $1.82 vs $1.51; adjusted EPS $1.84 vs $1.52.","FY 2025 net sales guidance raised to $3.04-3.06B (from $2.945-2.975B); adjusted EPS raised to $6.65-6.85.","Proprietary Products sales $619.8M (+10.7%); HVP components up 11.3% driven by GLP-1 elastomer growth.","Board declares Q4 dividend $0.22/share, payable Nov 19, record Nov 12.","First-half 2025 free cash flow $160M (from $92.4M); repurchased 552,593 shares for $134M."],"consensus_eps_estimate":1.5247,"consensus_eps_actual":3.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1464500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133592,"accession_number":"0000105770-25-000058","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma names Robert McMahon CFO effective Aug 4; Birkett to advise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McMahon to receive $800k base salary, target bonus 80% of base, LTI award of $3M on Aug 11.","One-time cash sign-on bonus of $3.115M and replacement equity grant of $4.2M for forfeited prior comp.","McMahon previously CFO at Agilent (2018-2025) and Hologic; 20 years at Johnson & Johnson.","Outgoing CFO Bernard Birkett will serve as Senior Advisor to CEO through Dec 31, 2025 for transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150281,"accession_number":"0000105770-25-000043","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K/A","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma shareholders approve amended 2016 Omnibus Plan; share reserve increased by 2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment effective May 6, 2025; total share reserve increased to 7,500,000 from 5,500,000.","Full value awards granted on/after May 6, 2025 count as 2.0 shares vs. 2.5 previously, reducing per-award dilution.","Most awards subject to minimum 12-month vesting; up to 5% of shares exempt from this requirement.","Non-employee director annual compensation cap raised to $800,000 (including cash).","Plan term extended to May 6, 2035; awards outstanding upon termination remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150285,"accession_number":"0000105770-25-000039","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"West Pharmaceutical shareholders approve all proposals at 2025 annual meeting; adopt special meeting right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 12 director nominees; highest vote against was Deborah Keller (7.4M against).","Advisory vote on executive compensation approved with 59.2M for, 3.5M against (91.4% support).","Articles amended to allow shareholders to call special meetings, approved with 62.7M for (99.9% for).","2016 Omnibus Incentive Compensation Plan amended and restated, approved with 60.9M for (97.0% for).","PricewaterhouseCoopers ratified as auditor for 2025 with 60.5M for, 4.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150284,"accession_number":"0000105770-25-000031","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma CFO Birkett to retire; Campbell named Chief Proprietary Segment Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Bernard Birkett informed West of intention to retire; search for successor initiated; will remain until transition and then advisory role through Dec 31, 2025.","Shane Campbell appointed SVP, Chief Proprietary Segment Officer effective May 5, 2025; previously at Carlisle Companies and DuPont.","Campbell receives $600K base salary, 75% target bonus (2025 prorated), $1M LTI award (50% PSUs, 25% options, 25% RSUs), $400K sign-on RSU (4-year vest), and $100K sign-on cash bonus.","Birkett joined West in June 2018 and served as CFO, also as CFO & COO from 2022 to April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150283,"accession_number":"0000105770-25-000029","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Q1 sales $698M (+0.4%), adj. EPS $1.45; raises FY2025 net sales and adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $698.0M (+0.4% reported, +2.1% organic); reported EPS $1.23 vs $1.55 YoY; adj. EPS $1.45 vs $1.56 YoY.","Full-year 2025 net sales guidance raised to $2.945B-$2.975B (prior $2.875B-$2.905B); adj. EPS guidance raised to $6.15-$6.35 (prior $6.00-$6.20).","Q3 2025 dividend declared at $0.21/share, payable Aug 6, 2025 to holders of record July 30, 2025.","Free cash flow $58.1M (up from $27.6M YoY); repurchased 550,281 shares for $133.5M in Q1.","Guidance includes $20-25M net impact from tariffs; organic net sales growth expected ~2%-3% for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":698000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150282,"accession_number":"0000105770-25-000022","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma SVP & Chief Commercial Officer departs; severance agreed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cindy Reiss-Clark left as SVP and Chief Commercial Officer on March 7, 2025.","Severance includes 52-week salary continuation ($489,500), pro-rated AIP ($57,526), and $15K outplacement.","Agreement includes a full release, noncompetition, nonsolicitation, and nondisparagement covenants.","Equity vesting ends March 7, 2025; 2024 AIP bonus of $42,476 to be paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169283,"accession_number":"0000105770-25-000019","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma CCO Cindy Reiss-Clark departs; interim lead named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cindy Reiss-Clark, SVP and Chief Commercial Officer, departed effective March 7, 2025.","Interim leadership of commercial responsibilities assumed by Aileen Kinsella, Head of Proprietary Product Sales.","Company thanked Reiss-Clark for her contributions; no reason for departure disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169282,"accession_number":"0000105770-25-000007","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.","FY 2025 guidance: net sales $2.875B-$2.905B; adjusted EPS $6.00-$6.20 (vs. FY24 $6.75).","Proprietary Products Q4 HVP sales were 74% of segment; Biologics unit had high-single-digit organic growth.","FY 2024 free cash flow $276.4M, down 33.3%; $560.9M spent on share repurchases during year.","CEO cited improving HVP trends in Biologics/Generics and growth from Annex 1 and GLP-1."],"consensus_eps_estimate":null,"consensus_eps_actual":6.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":2893200000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186317,"accession_number":"0000105770-24-000088","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"West Pharmaceutical authorizes repurchase of up to 550,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved new share repurchase program on Dec 9, 2024, authorizing up to 550,000 shares.","Repurchases may be made on open market or in private transactions under Rule 10b-18.","Program expected to be completed by December 31, 2025.","Existing repurchase program expires at end of 2024.","Repurchase timing and number depend on market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186316,"accession_number":"0000105770-24-000084","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"West Pharmaceutical appoints Janet Haugen to Board of Directors; former Unisys CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Janet Haugen elected to Board effective Dec 9, 2024; board size increases to 12 directors.","Haugen served as Unisys CFO for over 16 years and previously a partner at Ernst & Young.","She will receive standard non-employee director compensation: $100k annual retainer plus $220k RSU grant prorated.","Haugen also serves on boards of Bentley Systems, Juniper Networks, and CentralSquare Technologies.","She will join the Audit Committee of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186315,"accession_number":"0000105770-24-000075","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q3 EPS $1.85 (down from $2.14); raises FY2024 guidance, boosts dividend 5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $746.9M flat YoY; reported EPS $1.85 vs $2.14; adjusted EPS $1.85 vs $2.16.","FY2024 guidance raised: net sales $2.875B-$2.905B, adjusted EPS $6.55-$6.75 (prior $6.35-$6.65).","Dividend increased 5% to $0.21/share, payable Nov 20, 2024, record Nov 13, 2024.","Proprietary Products net sales $601.4M (-0.2%); Contract-Manufactured $145.5M (+0.4%).","Nine-month free cash flow $191.2M (-32.7%); share repurchases $506.5M in 9M 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":4.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":2144400000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186314,"accession_number":"0000105770-24-000071","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"West Pharma CTO Silji Abraham resigns effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Silji Abraham, SVP & Chief Technology Officer, notified resignation on Oct 1, 2024.","Departure effective December 31, 2024; he leaves to pursue other interests.","Company states departure is not due to any disagreement on operations, policies, or practices.","No additional compensation or severance will be provided in connection with the resignation.","Transition plan involves working with Abraham and his leadership team to ensure smooth handover."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202940,"accession_number":"0000105770-24-000060","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q2 net sales miss; slashes FY 2024 EPS guidance by over $1.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $702.1M, down 6.9% YoY; reported diluted EPS $1.51 vs $2.06; adj. EPS $1.52 vs $2.11.","Proprietary Products sales fell 9.4% to $559.7M; customer destocking continues, especially in Generics.","FY 2024 net sales guidance cut to $2.87-2.90B from $3.00-3.025B; adj. EPS lowered to $6.35-6.65 from $7.63-7.88.","First-half free cash flow fell 38.3% to $92.4M; company repurchased 1.24M shares for $454.1M at avg $366.53.","Management expects organic growth to return in Q4 and 2025; capex guidance raised to $375M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1397500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202939,"accession_number":"0000105770-24-000055","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"West enters $130M incremental term loan to refinance existing debt and notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On July 2, 2024, West Pharmaceutical Services entered a Third Amendment to its Credit Agreement, establishing a $130.0 million incremental term loan.","The new term loan was fully drawn at closing and matures on July 2, 2027, with no scheduled amortization.","Proceeds repaid an outstanding ~$80 million term loan and ~$53 million of 3.82% Series B Senior Notes due July 5, 2024.","Interest at closing is 3-month SOFR plus 1.250%, with margins ranging from 1.250% to 1.625% based on net leverage ratio.","Mandatory prepayments apply for asset sales and non-permitted debt issuances; optional prepayments are allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219148,"accession_number":"0000105770-24-000035","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"West CFO Bernard Birkett transitions to sole CFO; operating duties decentralized","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Bernard Birkett's role narrowed from CFO & COO to solely CFO effective May 1, 2024; operating leadership moves to business segments.","Shareholders elected 11 directors, approved say-on-pay (96.1% for), and ratified PricewaterhouseCoopers as auditor.","Charter amendments eliminating supermajority requirements for transactions and amendments approved with over 99% support.","A shareholder proposal on redundant topics was not presented after SEC no-action letter in West's favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219147,"accession_number":"0000105770-24-000025","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.","Net sales $695.4M, down 3.0% organically; Proprietary Products sales down 4.0%.","Full-year 2024 net sales guidance reaffirmed at $3.000-3.025B; adjusted EPS guidance raised to $7.63-7.88 from $7.50-7.75.","Board declares Q3 dividend $0.20/share, payable Aug 7, 2024 to holders of record Jul 31.","Repurchased 729,679 shares for $267M at avg $365.87 in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":695400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239023,"accession_number":"0000105770-24-000009","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).","Q4 reported EPS $1.83 (+34.6% YoY); full-year reported EPS $7.88 (+1.9% YoY).","FY24 guidance: net sales $3.000B-$3.025B; adjusted EPS $7.50-$7.75; organic sales growth ~2%-3%.","Proprietary Products organic sales down 0.3% Q4; COVID headwinds cited; excluding COVID, high-single-digit growth.","FY23 free cash flow $414.5M (down 5.7%); repurchased 1.27M shares for $438.3M at avg $346.34."],"consensus_eps_estimate":null,"consensus_eps_actual":7.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":2949800000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256509,"accession_number":"0000105770-23-000075","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"West Pharmaceutical extends butyl polymer supply agreement with ExxonMobil through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment secures supply of butyl polymers, a key raw material for pharmaceutical packaging, from 2024 to 2028.","Pricing includes base price plus adjustments based on Brent crude, UK natural gas, and USGC isobutylene indices (redacted).","Product qualification at Baton Rouge plant waives isobutylene adjustment during contract term as incentive.","New sustainability collaboration provision added, with joint discussions on activities and milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256508,"accession_number":"0000105770-23-000064","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.","Reported diluted EPS $2.14 (+34.6%); adjusted diluted EPS $2.16 (+6.4%).","FY2023 net sales guidance cut to $2.950-2.960B (from $2.970-2.995B); organic growth now 2-3%.","FY2023 adjusted EPS guidance raised to $7.95-8.00 (from $7.65-7.80); dividend increased to $0.20/share (+5.3%).","Proprietary Products net sales +6.3% (organic +3.2%); Contract-Mfg +20.8% (organic +17.4%)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2217800000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273899,"accession_number":"0000105770-23-000054","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K/A","filed_at":"2023-09-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"West Pharma board sets annual Say-on-Pay votes through 2029 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted annual frequency for future Say-on-Pay advisory votes, effective until 2029.","Decision follows non-binding shareholder recommendation at April 25, 2023 annual meeting.","Amendment filed solely to disclose this frequency decision; no other changes to prior 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273900,"accession_number":"0000105770-23-000043","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.","Net sales declined 2.3% to $753.8M; organic net sales fell 2.5%.","Proprietary Products segment sales down 5.5% to $618.0M, driven by COVID-19 related decline; base business grew double digits.","Contract-Manufactured Products segment sales up 15.3% to $135.8M, led by injection-device components.","FY2023 net sales guidance raised to $2.970-2.995B; adjusted EPS guidance raised to $7.65-7.80."],"consensus_eps_estimate":null,"consensus_eps_actual":3.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1470400000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291000,"accession_number":"0000105770-23-000026","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"West Pharmaceutical shareholders elect all directors, approve say-on-pay, reject fair elections proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; each received >60M votes for with minimal against.","Advisory say-on-pay approved with 95.3% of votes cast in favor (62.3M for).","Ratification of PwC as auditor approved with 92.2% of votes cast (62.2M for).","Advisory vote on frequency: 1 year selected with 98.7% of votes cast (64.5M for 1 year).","Shareholder proposal on fair elections rejected: 89.2% of votes cast against (58.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290999,"accession_number":"0000105770-23-000018","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma reports Q1 2023 net sales $716.6M, adjusted EPS $1.98; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $716.6M (down 0.5% YoY); organic sales growth 2.3%. Reported diluted EPS $1.85 (down 19.2%); adjusted diluted EPS $1.98 (down 13.9%).","Raised FY2023 net sales guidance to $2.965-2.990B from $2.935-2.960B; adjusted EPS guidance to $7.50-7.65 from $7.25-7.40.","Proprietary Products segment net sales $583.1M (down 3.0%); Biologics market unit organic sales declined double-digits due to lower COVID-19 sales.","Operating cash flow $138.1M; free cash flow $56.0M (down 34.4%). Repurchased 183,360 shares for $60.1M at avg price $327.90.","Board approved Q3 2023 dividend $0.19/share payable Aug 2, 2023 to holders of record Jul 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":716600000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311826,"accession_number":"0000105770-23-000004","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.","Full-year 2022 net sales $2.887B (+2.0% reported, +7.7% organic); reported EPS $7.73, adjusted EPS $8.58.","FY 2023 guidance: net sales $2.935-2.960B, adj. EPS $7.25-7.40; COVID sales ~$85M (vs $388M in 2022).","Board approved new $1.0B share repurchase program, no expiration; prior program expired Dec 31, 2022.","Operating cash flow $724.0M (+24%); free cash flow $439.4M (+32.9%); capex $284.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":7.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":2886900000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330389,"accession_number":"0000105770-22-000050","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.","Reported EPS $1.59 (-31.2%); adjusted EPS $2.03 (-1.5%); Biologics and Generics mid-single digit organic growth.","FY2022 guidance cut: net sales $2.830-2.840B (prior $2.950-2.975B), adjusted EPS $8.15-8.20 (prior $9.00-9.15).","Dividend raised 5.6% to $0.19/share, payable Nov 16 to holders of record Nov 9; 30th consecutive annual increase.","Management cited delays in expansion projects and customer mix-shift; expects resolution early 2023; capex guidance lowered to $300-320M."],"consensus_eps_estimate":null,"consensus_eps_actual":6.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":2178200000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347945,"accession_number":"0000105770-22-000042","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q2 net sales $771M (+6.6%); cuts FY2022 guidance on FX and COVID decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $771.3M (+6.6% reported, +13.1% organic); reported EPS $2.48, adjusted EPS $2.47.","Proprietary Products segment sales $653.7M (+11.3%, organic +18.3%) led by high-value components and devices.","Contract-Manufactured Products sales $117.8M (-13.6%, organic -8.9%) on lower diagnostic device component sales.","FY2022 guidance cut: net sales now $2.950-$2.975B (prior $3.050-$3.075B); adjusted EPS $9.00-$9.15 (prior $9.30-$9.45).","Guidance reflects $190M FX headwind and ~$85M decline in COVID-19 sales; base business growth partially offsets."],"consensus_eps_estimate":null,"consensus_eps_actual":4.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":1491300000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347944,"accession_number":"0000105770-22-000038","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"West Pharma adds Dr. Stephen Lockhart as director; $90K retainer + $190K RSU","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected July 26, 2022; Board expands to 11 members.","Dr. Lockhart, former CMO of Sutter Health, appointed to Innovation & Technology and Finance Committees.","Receives prorated $90,000 annual cash retainer and $190,000 annual RSU grant (grant date Aug 1, 2022).","Also eligible for Director Deferred Compensation Plan and standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364512,"accession_number":"0000105770-22-000026","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"West Pharmaceutical shareholders elect all 10 directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Robert F. Friel received highest votes (64.97M for).","Advisory say-on-pay approved: 61.05M for, 4.44M against, 0.13M abstain.","PricewaterhouseCoopers ratified as auditor: 62.26M for, 5.98M against, 0.10M abstain.","91.91% of outstanding shares represented at the virtual annual meeting.","Broker non-votes of 2.71M recorded for director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364511,"accession_number":"0000105770-22-000021","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"West Pharma appoints CFO Birkett to combined CFO/COO role; Montecalvo resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernard J. Birkett assumes expanded role as Chief Financial and Operations Officer, leading Global Operations and Supply Chain in addition to CFO duties.","David Montecalvo, SVP Chief Global Operations and Supply Chain Officer, resigns to pursue other interests; departure expected July 2022.","Cindy Reiss-Clark appointed as Chief Commercial Officer, leading global commercial strategy.","Changes effective May 12, 2022, as announced in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364510,"accession_number":"0000105770-22-000014","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma Q1 net sales $720M (+7.4%), adj. EPS $2.30; raises FY2022 adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $720.0M (+7.4% YoY); organic sales growth 11.0%.","Reported diluted EPS $2.29 (+15.1%), adjusted diluted EPS $2.30 (+12.2%).","Raises FY2022 adjusted EPS guidance to $9.30-$9.45 from $9.20-$9.35; reaffirms net sales $3.05B-$3.075B.","Q3 dividend $0.18/share, payable Aug 3, record Jul 20; repurchased 390k shares for $147.1M.","Proprietary Products segment sales $601.3M (+10.6%); HVP organic growth double-digit."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":720000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364509,"accession_number":"0000105770-22-000010","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"West Pharma amends credit facility to $500M, extends to 2027; adds Japanese subsidiary as borrower","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Increased credit facility from $300M to $500M senior unsecured revolving; maturity extended to March 31, 2027.","Added West Pharmaceutical Services Holding Japan Godo Kaisha as additional borrower under the facility.","Interest: Term SOFR + 0.10% + margin of 87.5-137.5 bps or base rate + 0-37.5 bps.","Financial covenant: Net Consolidated Debt to modified EBITDA ratio max 3.5:1 (4.0:1 for qualified acquisitions up to 4 quarters)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384197,"accession_number":"0001628280-22-004277","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chairman Patrick Zenner to retire; CEO Eric Green becomes Chair; Lead Independent Director appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Zenner to retire from Board at May 24, 2022 Annual Meeting after 20 years; no disagreement with Company.","President & CEO Eric M. Green will succeed Zenner as Chairman of the Board.","Paolo Pucci appointed Lead Independent Director, effective at the Annual Meeting.","Roles of Chair and CEO combined; Pucci will liaise between Green and Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384196,"accession_number":"0001628280-22-002935","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC","ticker":"WST","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.","Full-year reported diluted EPS $8.67 (+90%); adjusted diluted EPS $8.58 (+80%).","Proprietary Products segment Q4 sales $609.3M (+34.2%), driven by high-value product growth across all market units.","FY2022 guidance: net sales $3.050-$3.075B (~10% organic growth), reported EPS $9.20-$9.35, capex $380M.","Operating cash flow $584M (+23.6%), free cash flow $330.6M (+10.9%)."],"consensus_eps_estimate":null,"consensus_eps_actual":8.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2831600000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21471920000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}